Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612170 · ClinicalTrials.gov registry record · Phase 3
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,129
- Enrollment target
NCT00612170 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,129 participants.
The verdict
NCT00612170, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,129 participants
- Enrollment target
Study Summary
This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.
Interventions
- DRUG Placebo
- DRUG [S,S]-Reboxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,129 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612170
The ClinicalTrials.gov registry entry for NCT00612170 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00612170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612170 about?
NCT00612170 is a clinical study titled "A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.". This is a study to investigate the effectiveness and safety of \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients. A previous study demonstrated clinically meaningful treatment effects in fibromyalgia, based on pain and functional endpoints.
What is the current status of trial NCT00612170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,129 participants. The study started on 2007-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00612170?
The interventions under investigation include: Placebo (DRUG), [S,S]-Reboxetine (DRUG).
Who is sponsoring clinical trial NCT00612170?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.